Nateglinide combination therapy with basal insulin and metformin in patients with Type 2 diabetes

Juurinen, Leena; Tiikkainen, Mirja; Saltevo, Juha; Nikkilä, Katriina; Lanki, H.; Leppävuori, E.; Köck, Thomas; Teikari-Myyrä, T.; Kauppinen‐Mäkelin, Ritva; Kotronen, Anna; Yki‐Järvinen, Hannele

doi:10.1111/j.1464-5491.2009.02691.x

Cited by 9 publications

(2 citation statements)

References 19 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, certain patients are not able to achieve even more modest HbA1c targets with basal insulin alone . In most circumstances, when additional therapies, including non‐insulin agents, are used in combination with basal insulin, hypoglycaemia rates increase compared with the use of insulin monotherapy . One drug class, the dipeptidyl peptidase‐4 (DPP‐4) inhibitors, increases ambient concentrations of the endogenously secreted incretins of the gastrointestinal tract, glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic peptide (GIP) .…”

Section: Introductionmentioning

confidence: 99%

Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes

Inzucchi

Nauck

Hehnke

et al. 2015

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes

Inzucchi

Nauck

Hehnke

et al. 2015

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

show abstract

“…In older people, treatment with nateglinide, alone or in combination with metformin, is well tolerated and produces significant improvements in glycaemic control . Similarly, nateglinide improves postprandial hyperglycaemia when added to the combination of basal insulin and metformin, but increases the frequency of hypoglycaemia . Interestingly, the glucose‐lowering effect of nateglinide is less potent than that for repaglinide, despite their similar postprandial glycaemic effects.…”

Section: Oral Agentsmentioning

confidence: 99%

Pharmacological treatment of diabetes in older people

Valencia

Flórez

2014

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

The pharmacological management of diabetes in older people is complex and challenging. It requires a comprehensive understanding of the individual beyond the diabetes itself. Through the ageing years, the older individual presents with diabetes-related and non-related comorbidities and complications, develops functional limitations and psychological issues, and may lack social support and access to care. A disturbance in these categories, known as the four geriatric domains, will negatively affect diabetes self-management and self-efficacy, leading to poor outcomes and complications. Furthermore, older people with diabetes may be more interested in the management of other chronic conditions such as pain or impaired mobility, and diabetes may be lower in their list of priorities. Proper education must be provided to the older individual and caregivers, with continuous monitoring and counselling, especially when pharmacological interventions offer risks of side effects, adverse reactions and interactions with other medications. Informed shared medical decisions will help to improve adherence to the regimen; however, such discussions ought to be based on the best evidence available, which is unfortunately limited in this age group. We performed a review focused on pharmacological agents and summarize current evidence on their use for the treatment of diabetes in older people. We encourage clinicians to investigate and incorporate the four geriatrics domains in the selection and monitoring of these agents.

show abstract

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus

Salpeter

Greyber

Pasternak

et al. 2010

Cochrane Database of Systematic Reviews

297

144

View full text Add to dashboard Cite

Nateglinide combination therapy with basal insulin and metformin in patients with Type 2 diabetes

Abstract: Addition of a short-acting insulin secretagogue at main meals improves postprandial hyperglycaemia during combination therapy with basal insulin and metformin, but increases the frequency of hypolycaemia.

Cited by 9 publications

References 19 publications

Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes

Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes

Pharmacological treatment of diabetes in older people

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus

Contact Info

Product

Resources

About